MedPath

Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma

Phase 2
Completed
Conditions
Esophageal Cancer
Registration Number
NCT00230451
Lead Sponsor
University of Michigan Rogel Cancer Center
Brief Summary

Surgery (esophagectomy or removal of the esophagus)has been the standard treatment for cancer of the esophagus. However, evidence suggests that preoperative chemotherapy and radiation therapy may add benefit. The purpose of this study is to determine if a treatment program of combined chemotherapy and radiation therapy prior to surgery and chemotherapy after surgery will delay or eliminate recurrence of the cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Read More
Exclusion Criteria
  1. Patients with active infection, pregnancy, lactating females, serious inter-current medical conditions including congestive heart failure, cardiac arrhythmias, or symptomatic coronary artery diseases are ineligible.
  2. No prior treatment allowed. No prior thoracic radiation.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
To determine the rate of complete histologic response induced by this neoadjuvant chemotherapy and radiation therapy regimen.
Secondary Outcome Measures
NameTimeMethod
To assess the qualitative and quantitative toxicities of this regimen.
To determine the overall survival and time to relapse in patients treated with preoperative chemotherapy and radiation therapy followed by adjuvant combination chemotherapy.

Trial Locations

Locations (1)

University of Michigan Cancer Center

🇺🇸

Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath